Licofelone
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
ECHA InfoCard | 100.222.821 |
| Chemical and physical data | |
| Formula | C23H22ClNO2 |
| Molar mass | 379.88 g·mol−1 |
| |
  (what is this?) (verify) | |
Licofelone is a dual
COX/LOX inhibitor[1][2] that was studied in clinical trials as a treatment for osteoarthritis[3] and which was under development
by Merckle GmbH with partners Alfa Wassermann and Lacer.
Licofelone is both an analgesic and an anti-inflammatory. Inhibition of
nonsteroidal anti-inflammatory drugs (NSAID), which only inhibit cyclooxygenase
(COX). Licofelone is the first drug to inhibit both.
Phase III trials for osteoarthritis were conducted in the early 2000s,[4][5] but results were mixed and the drug has never been submitted for regulatory approval.